China's Innovative Drug Licensing Deals Near Full-Year 2023 Volume in H1 2024
China's innovative drug sector is showing significant progress, with the scale of external licensing deals in the first half of 2024 approaching the total volume seen in all of 2023. This update was revealed by a representative from the National Medical Products Administration's (NMPA) Drug Registration and Administration Department at the Beijing Changping Life Science Forum on the 12th. The NMPA previously reported that China aimed to approve 76 innovative drugs by 2025. While the number of approvals reached a historic high this year, only 4 out of the 11 newly approved drugs with novel targets and mechanisms were domestically developed. This indicates that the number of domestically developed first-in-class innovative drugs (those with new targets and mechanisms) approved so far this year has already surpassed the entire previous year's total and is expected to set another new record.
The surge in external licensing of Chinese innovative drugs suggests a maturing domestic R&D landscape, increasingly capable of producing globally competitive therapeutics. This trend reflects a strategic shift from solely focusing on domestic market needs to engaging with international pharmaceutical markets through partnerships and licensing. Such international validation is crucial for long-term growth, potentially accelerating drug development timelines and expanding patient access worldwide. However, the data also highlights a persistent gap in domestic development of truly novel targets and mechanisms, with a majority of such breakthroughs originating from international sources. Future policy and investment may need to balance supporting commercialization and internationalization with fostering fundamental research to cultivate indigenous innovation at the earliest stages.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.